This paper is only available as a PDF. To read, Please Download here.
The efficacy, safety, and tolerability of a 5-day, once-daily course of azithromycin were assessed in patients with acute sinusitis. Patients received two 250-mg capsules of azithromycin on day 1 and once 250-mg capsule on days 2 through 5. Of 102 clinically assessable patients, 27 (26.5%) were cured and 69 (67.5%) were improved on days 5 to 7. At days 12 to 16, 88 (86.3%) had a favorable clinical response. A total of 64 patients experienced adverse events; in all but two patients, adverse events were of mild or moderate severity. Thus azithromycin given once daily for 5 days was an effective treatment for patients with acute sinusitis.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Comparison of acid stability of azithromycin and erythromycin A.J Antimicrob Chemother. 1990; 25 (Suppl A): 39-47
- Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homerythromycin A derivatives: A new class of macrolide antibiotics, the azalides.J Antibiot. 1988; 41: 1029-1047
- Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.Antimicrob Agents Chemother. 1987; 31: 1939-1947
- Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae.J Antimicrob Chemother. 1990; 25 (Suppl A): 25-28
- Comparative in vitro activities of 14-, 15- and 16-membered macrolides.Antimicrob Agents Chemother. 1988; 32: 1710-1719
- The pharmacokinetics of azithromycin in human serum and tissues.J Antimicrob Chemother. 1990; 25 (Suppl A): 73-82
- Azithromycin concentrations in sinus fluid and mucosa after oral administration.Eur J Clin Microbiol Infect Dis. 1991; 10: 856-859
- An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers.Eur J Clin Microbiol Infect Dis. 1991; 10: 850-852
- In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection.Antimicrob Agents Chemother. 1989; 33: 277-282
- In-vitro concentration of azithromycin in human phagocytic cells.J Antimicrob Chemother. 1993; 31 (Suppl E): 1-4
- Preferential concentration of azithromycin in an infected mouse thigh model.J Antimicrob Chemother. 1993; 31 (Suppl E): 5-16
- 49th ed. Physicians' Desk Reference®. Medical Economics Data Production Company, Montvale, NJ1995
- Short-course treatment of sinusitis and other upper respiratory tract infections with azithromycin: A comparison with erythromycin and amoxicillin.J Int Med Res. 1991; 19: 363-372
- Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis.Am J Med. 1991; 91 (Suppl 3A): 27S-30S
- Comparison of the effect of erythromycin clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters.Drug Invest. 1994; 7: 148-156
- Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450.Antimicrob Agents Chemother. 1991; 35: 1186-1190
- Azithromycin and terfenadine: Lack of drug interaction, a double-blind, placebo-controlled study.Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1993; (New Orleans, La Abstract #597)
© 1995 Published by Elsevier Inc.